Printer Friendly

Biotech communications firms schedule new investor conference focusing on specific diseases.

SAN MATEO, Calif.--(BUSINESS WIRE)--Nov. 29, 1994--BioVenture Publishing Inc. and Russell-Welsh Inc. Tuesday announced that they will jointly manage a new, disease-focused conference program for healthcare investment professionals, "Pathotropic Investing."

The first conference, focusing on emerging therapies for the growing market of gynecic diseases and disorders, will be held April 6-7, 1995, at the Four Seasons Hotel, Washington, D.C. The program will feature 15-20 biopharmaceutical and medical technology company presentations and special keynote speakers from the research and public policy sectors.

"When the momentum of product innovation and clinical progress in certain diseases reaches a critical mass, investors need to take note of significant developments in a timely fashion," said Cynthia Robbins-Roth, editor-in-chief of BioVenture.

"We are structuring our conference sessions around diseases and disorders where we believe the technical pace has quickened to such a level, thus representing a significant investing opportunity."

The spring conference will focus on emerging therapies for breast, ovarian and cervical cancer, osteoporosis and connective tissue diseases, reproductive disorders and the gynopathic inflammatory diseases -- rheumatoid arthritis, multiple sclerosis and lupus.

"In addition to benefiting from scientific and clinical advances, the gynecic diseases also are gaining from regulatory and public policy changes," Robbins-Roth said.

"Our institutional research has shown that many analysts and portfolio managers prefer disease-oriented programs through which they can evaluate alternative technologies being developed to address a given disorder," said Katharine A. Russell, president, Russell-Welsh.

"By focusing in one area and gaining exposure to companies developing a range of products in different development time frames, the prospective investor gains a broader insight into the competitive dynamic unfolding in a specific treatment area."

The organizers are in the process of finalizing the program for the two-day conference. The list of participating companies and a meeting agenda for the invitation-only program will be published before year end.

With world headquarters in San Mateo, BioVenture Publishing covers the business and finance of biotechnology with three publications targeted to the different needs of industry insiders -- BioVenture View, with in-depth industry analysis of companies, products and events, BioVenture Stock Report, with user-friendly financial charts of the top 100 biotherapeutic companies and BIOPEOPLE, featuring the personalities behind the business and science of biotechnology.

Russell-Welsh is a San Mateo-based public relations and investor relations agency providing consulting and services exclusively to public and private bioscience and medical technology companies. The company also maintains an office in Oceanside, Calif.

Inquiries about the conference should be directed to Evelyn Evans at Russell Welch 415/312-0700, or in the San Diego area to Kathy Day at 619/757-2434.

CONTACT: BioVenture Publishing Inc.
 Cynthia Robbins-Roth, 415/574-7128
 or
 Russell-Welsh Inc.
 Katharine A. Russell, 415/312-0700
COPYRIGHT 1994 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 29, 1994
Words:443
Previous Article:Autodesk strengthens data management strategy; acquires Sirlin Corp.
Next Article:Puma Technology's infrared software, TranXit, gives IBM ThinkPad users instant access to desktop files; TranXit for OEMs offers interoperable IR...
Topics:


Related Articles
Gene Dreams.
CIBC World Markets Bio-Technology Conference Highlights Breakthroughs in Antibodies, Genomics.
MPM CAPITAL LEADS EUR22 MILLION FINANCING OF BIOXELL.
Needham & Company, Inc. to Host Second Annual Biotech Conference; Biotechnology Under the Loop!
Active Biotech to present at UBS Global Life Sciences Conference.
Labor pool attracts biotech firm to NJ.
GPC BIOTECH/DEBIOPHARM SIGN MHC II ANTAGONISTS LICENSE PACT.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters